New research suggests that people who come off new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt traditional lifestyle plans.
Published data in a major medical journal demonstrates that while overweight individuals often shed substantial amounts of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Individuals using these drugs should be aware of the danger of fast weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of regain suggests a reversion to starting mass in about one and a half years.
Comparing Therapies
The analysis, which reviewed 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who shed pounds through dieting typically see a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Experts suggest the mechanism of the drugs accounts for the amplified rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Health authorities advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts contend that, considering the likelihood of relapse, the treatment should be considered long-term.
This opinion is reinforced by pharmaceutical companies, who say that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the medication explain a sudden return of hunger.
"I experienced a switch that goes on and you're instantly ravenous," described a patient.
This challenge is exacerbated if patients have not established sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Recent estimates suggest that millions of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is more common among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on integrated behavioural support.